context the womens health initiative memory study whims previously found increased risk for dementia and no effect on mild cognitive impairment mci in women treated with conjugated equine estrogens cee plus medroxyprogesterone acetate mpaobjective to determine the effects of cee alone and cee plus mpa on incidence of probable dementia and mci in older womendesign setting and participants randomized doubleblind placebocontrolled clinical trials of cee estrogenalone trial or cee plus mpa estrogen plus progestin trial in communitydwelling women aged 65 to 79 years conducted from june 1995 to july 8 2002 estrogen plus progestin n  4532 or to february 29 2004 estrogenalone n  2947 in 39 of the 40 whi clinical centersinterventions in the estrogenalone trial 1 daily tablet containing either 0625 mgd of cee vs matching placebo in the estrogen plus progestin trial 1 daily tablet containing cee 0625 mgd plus mpa 25 mgd vs matching placebosmain outcome measures probable dementia and mciresults in the estrogenalone trial 47 participants were diagnosed with probable dementia of whom 28 were assigned to cee and 19 to placebo hazard ratio hr 149 95 confidence interval ci 083266incidence rates for probable dementia in the estrogenalone trial were statistically similar to those in the estrogen plus progestin trial 45 vs 22 per 10 000 personyears for cee plus mpa vs placebo respectively p 11when data were pooled per the original whims protocol the overall hr for probable dementia was 176 95 ci 119260 p 005after excluding participants with baseline modified minimental state examination scores at or below the screening cut point the hr was 177 95 ci 074423 p 20 in the estrogenalone trial and 219 95 ci 125384 p 006 in the pooled trialsin the estrogenalone trial 76 participants were diagnosed with mci in the cee group vs 58 in the placebo group hr 134 95 ci 095189in the combined trial data the hr was similar 125 95 ci 097160in the estrogenalone trial 93 participants receiving cee were diagnosed with either probable dementia or mci vs 69 receiving placebo hr 138 95 ci 101189 p 04conclusions estrogen therapy alone did not reduce dementia or mci incidence and increased the risk for both end points combinedpooling data for estrogen alone and estrogen plus progestin resulted in increased risks for both end pointsuse of hormone therapy to prevent dementia or cognitive decline in women 65 years of age or older is not recommended